Symptomatic hyperviscosity is a well-established phenomenon in Waldenström macroglobulinemia (WM). Monoclonal IgM can variably impact intrinsic serum viscosity, leading to widely disparate symptomatic thresholds for development of hyperviscosity-related symptoms. Data regarding the predictors of symptomatic hyperviscosity and outcomes related to this complication remain scarce and a recent study proposed that IgM >6000 mg/dL be considered a new criterion for initiating therapy in otherwise asymptomatic (smoldering) WM to pre-empt hyperviscosity-related injury. Herein, we attempt to identify predictors of the development of symptomatic hyperviscosity and its impact in patients with WM. Of 997 WM patients evaluated from January, 1996 through June, 2017, symptomatic hyperviscosity was observed in 130 (13%) patients. Overall survival (OS) of these 130 patients was similar to that of patients without symptomatic hyperviscosity (median: 11.5 vs 11.6 years; P = 0.63). On multivariateanalysis, only viscosity >1.8 cp (risk ratio: 4.0, P = 0.02) assessed at the time of WM diagnosis was an independent predictor for the development of subsequent symptomatic hyperviscosity.
vision with the laboratory evaluation showing increased blood viscosity. [4] [5] [6] [7] Serious life-threatening complications associated with hyperviscosity are infrequent, but catastrophic complications such as stroke, hearing loss and retinal bleeding causing vision loss have been described. [8] [9] [10] Therefore, it is important to establish the predictors for the development of symptomatic hyperviscosity and to determine whether the risk of developing symptomatic hyperviscosity in patients with WM merits pre-emptive intervention to avoid major hyperviscosity-related injury.
The 2002 Consensus recommendations indicate that WMdirected therapy should be commenced in the setting of constitutional symptoms such as recurrent fever, night sweats, fatigue due to anemia, or weight loss, WM-associated hemoglobin <10 g/L, platelets <100 × 10 9 /L, bulky adenopathy and/or progressive organomegaly, symptomatic hyperviscosity, peripheral neuropathy, or co-existing amyloidosis, cryoglobulinemia, or cold-agglutinin disease. Traditionally, an isolated increase in serum IgM per se, in the absence of symptomatic hyperviscosity has not been considered a specific indication for initiation of treatment in WM.
11
A recent study involving previously untreated patients with WM suggested that serum IgM >6000 mg/dL at diagnosis is associated with a high risk of developing hyperviscosity syndrome (HVS), within a median of 3 months, and the investigators recommended preemptive initiation of therapy at a serum IgM threshold of 6000 mg/ dL. 12 However, the study lacked information on the serum viscosity of patients. It has been observed that individual monoclonal serum IgM proteins can have significant variation in their impact on intrinsic viscosities. 13, 14 Individual patients tend to have a "symptomatic threshold" and the serum IgM levels required for the development symptomatic hyperviscosity can vary widely based upon the properties of their serum IgM molecule. 3, 5 Serum viscosity, on the other hand, has been found to be an important predictor for the development of symptomatic hyperviscosity. 2, 3, 15 The relative serum viscosity measured by a validated method tends to be highly reproducible for an individual IgM protein and can overcome the limitation of the variation in intrinsic viscosities associated with the serum IgM molecules. 5 Data about the predictors of symptomatic hyperviscosity in patients with WM remain sparse. Herein, we present a single-center experience of patients with WM who developed symptomatic hyperviscosity to delineate the factors associated with the development of symptomatic hyperviscosity and to assess any correlation of serum IgM >6000 mg/dL with the development of symptomatic hyperviscosity meriting commencement of treatment in patients with otherwise smoldering WM.
| METHODS
All patients with a definitive diagnosis of WM, defined as the presence of circulating IgM monoclonal protein of any size and ≥10% bone marrow infiltration with lymphoplasmacytic lymphoma (LPL) 1 seen consecutively between January 1st, 1996 and June 30th, 2017 at Mayo Clinic, Rochester, were included in the study. were performed using the Kaplan-Meier method. 21 The differences between survival curves were tested for statistical significance with the log-rank test. A P-value <0.05 was considered statistically significant. All analyses were performed using JMP 13.0 software (SAS Institute, Cary, NC).
| RESULTS
Of 997 patients with WM, 130 (13%) patients were found to have symptomatic hyperviscosity, either at the time of diagnosis of WM (n = 68), or subsequently during the disease course (n = 62). A comparison of the baseline clinical characteristics of patients with and without symptomatic hyperviscosity is shown in Table 1a . Lactate dehydrogenase above normal, (>222 U/L), n (%) 8 (14) 37 (14) 0.9 Baseline characteristics and laboratory parameters at diagnosis of WM in patients with symptomatic hyperviscosity at WM diagnosis compared to the patients without symptomatic hyperviscosity during their disease course (14) 37 (14) 0.9 Lactate dehydrogenase above normal, (>222 U/L), n (%) 4 (14) 37 (14) 0.9
*% rounded to nearest whole number. The median follow-up of the entire cohort was 8.8 years (95% CI:
8.1-9.6). The median OS for the entire cohort was 11.6 years (95% CI:
10.7-12.2). The median OS for patients, with and without symptomatic hyperviscosity was similar; 11.5 years (95% CI: 9.5-14.3) and 11.6 years (95% CI: 10.7-12.5), respectively, P = 0.63; Figure 1A . Additionally, 
| Serum IgM and viscosity at the time of symptomatic hyperviscosity
Of the 130 patients, 101 (78%) had an IgM level available at the time of symptomatic hyperviscosity. Among those, 3%, 22%, 45%, and 30%
had IgM level of 0-3000 mg/dL, 3001-6000 mg/dL, 6001-9000 mg/ dL and above 9000 mg/dL, respectively. Similarly, of 130 patients with symptomatic hyperviscosity, 85 (65%) had serum viscosity available at the time of symptomatic hyperviscosity. Among these 85 patients, 42 (49%) developed typical symptoms/signs of hyperviscosity with serum viscosity of ≥4 cp vs 43 (51%) with serum viscosity value of <4 cp, P = 0.76.
| Predictors of time to development of symptomatic hyperviscosity in newly diagnosed, previously untreated WM patients
Patients with symptomatic hyperviscosity at diagnosis (n = 68), those who received systemic therapy prior to developing symptomatic hyperviscosity (n = 37) and those who lacked the documentation of the date of symptomatic hyperviscosity in their medical records (n = 8) were excluded from the analysis of data to ascertain the pre- The findings of the univariate and multivariate analyses for time to development of symptomatic hyperviscosity are outlined in Table 3 and all the variables used in these analyses were from time of WM diagnosis. Of all the variables included in the univariate analysis, serum viscosity (P = 0.005) and serum IgM (P = 0.02) were found to be significant predictors of time to development of symptomatic hyperviscosity.
Cutoffs of serum IgM >2800 mg/dL and serum viscosity >1.8 cp were derived by ROC curve analysis and were used for dichotomizing these continuous variables. Serum viscosity >1.8 cp and serum IgM >2800 mg/dL were significant predictors of development of symptomatic hyperviscosity on univariate analysis (Table 3) . However, in a bivariate analysis involving these two variables, only serum viscosity of >1.8 cp remained an independent predictor of the time to development of symptomatic viscosity [risk ratio: 4.0 (95% CI: 1.3-15.7), P = 0.02; Table 3 ]. In patients with a serum viscosity >1.8 cp at FIGURE 1 (A) Overall survival (OS) of patients with symptomatic hyperviscosity at any point during WM disease course compared to patients without symptomatic hyperviscosity. Median OS for patients with symptomatic hyperviscosity at any point during WM disease course and without symptomatic hyperviscosity at any point of WM disease course was 11.5 years (95% CI: 9.6-14.3) and 11.6 years (95% CI: 10.7-12.5), respectively (P = 0.63). (B) Overall survival (OS) of patients with symptomatic hyperviscosity at WM diagnosis compared to patients without symptomatic hyperviscosity. Median OS for patients with symptomatic hyperviscosity at WM diagnosis and without symptomatic hyperviscosity at any point of WM disease course was 12.3 years (95% CI: 9.6-NR) and 11.6 years (95% CI: 10.7-12.5), respectively (P = 0.35). (C) Overall survival (OS) of patients with symptomatic hyperviscosity not at WM diagnosis compared to patients without symptomatic hyperviscosity. Median OS for patients with symptomatic hyperviscosity not at WM diagnosis and without symptomatic hyperviscosity at any point of WM disease course was 10.5 years (95% CI: 9.1-13.2) and 11.6 years (95% CI: 10.7-12. Figure 1E ).
| Treatment of symptomatic hyperviscosity
The median number of episodes of symptomatic hyperviscosity during There was no difference in the survival outcome of patients who developed symptomatic hyperviscosity during their disease course compared to those who did not develop symptomatic hyperviscosity during their disease course. Additionally, the timing of symptomatic hyperviscosity, whether at diagnosis of WM or subsequently during the disease course, did not affect OS compared to patients without symptomatic hyperviscosity. A majority of patients underwent plasma exchange for hyperviscosity related symptoms which was a welltolerated procedure leading to adverse effects such as hypocalcemia, hypotension, dizziness in less than 5% of patients which mirrors previously published data regarding the rate of adverse effects of plasma exchange at 4.75%. 25 A recently published study, 12 evaluating previously untreated WM patients demonstrated that 37 of 825 (4.5%) patients had serum
IgM >6000 mg/dL at diagnosis. While it is unclear from that report as to how many subjects were truly smoldering, that is, not exhibiting other signs/symptoms or laboratory values requiring initiation of therapy, after excluding the patients who presented with HVS at WM diagnosis the authors found that 31 of 37 (84%) patients developed HVS within a median time of 3 months. 12 This study is somewhat limited by the absence of serum viscosity-related data as well as information regarding the number of patients receiving therapy from the time of diagnosis of WM to the onset of HVS. Additionally, the data with respect to the concurrent presence of other indications for initiation of therapy as per the Consensus criteria were not shown. 12 In contrast, our study, has a larger proportion of treatment-naïve patients with serum IgM >6000 (n = 132) at diagnosis of WM. After excluding the patients who presented with symptomatic hyperviscosity at diagnosis (n = 49) from this group of patients with serum IgM >6000 mg/ dL and with a follow-up of approximately 9 years, the median time to development of symptomatic hyperviscosity was not reached, and only 2.5% of patients developed symptomatic hyperviscosity within 3 months of their diagnosis. Also, of the 13 patients who otherwise had smoldering WM in the setting of serum IgM >6000 mg/dL at WM diagnosis, only 2 (15%) developed symptomatic hyperviscosity and neither of these two patients had a catastrophic event that could have justified pre-emptive therapy. Moreover, the median time to initial therapy was 6.9 years in this cohort of patients with smoldering WM, an interval that was comparable to the remainder of smoldering WM patients that had a baseline serum IgM ≤6000 mg/dL at diagnosis of WM. This observation suggests that the need for therapy may not be dictated by the serum IgM levels in otherwise asymptomatic patients. Furthermore, a majority of patients (90%) with serum IgM >6000 mg/dL at diagnosis already had an established clear indication for initiation of therapy per the Consensus criteria. 11 Hence, the risk of symptomatic hyperviscosity in otherwise asymptomatic patients with a serum IgM >6000 mg/dL remains low. Therefore, the findings of our study suggest that elevated serum IgM levels in isolation should not to be used as an indicator for pre-emptive therapy in otherwise asymptomatic patients.
Our study also found age, bone marrow LPL percentage, serum IgM, hemoglobin, platelet count and involved to uninvolved free light chain ratio at the time of diagnosis of WM to be different in patients who had symptomatic hyperviscosity at any point in their disease course (diagnosis or subsequently) compared to patients who did not develop symptomatic hyperviscosity during their follow-up. Most of these variables are direct or indirect measures of the disease burden, which can correlate with the risk of symptomatic hyperviscosity and is the probable explanation for the difference seen in these groups. In a recent study, a lower hemoglobin level, younger age, higher serum IgM level as well as higher percentage of bone marrow involvement by LPL at diagnosis of WM were observed in patients who had HVS at any point of their disease course compared to patients who did not. 12 Further, patients who did not have symptomatic hyperviscosity at any point during the disease course had a higher median serum LDH level at WM diagnosis compared to patients who had symptomatic hyperviscosity at WM diagnosis. The exact reason for this difference at this point remains unclear. The proportion of patients exhibiting MYD88 L265P mutation was similar in patients with or without symptomatic hyperviscosity in this study 12 which was consistent with the findings of our study as well.
When assessing the predictors of time to development of symptomatic hyperviscosity, on a multivariate analysis, only serum viscosity >1.8 cp was found to be an independent predictor of time to development of symptomatic hyperviscosity. This observation is consistent with our prior knowledge that the viscosity at a particular IgM level can vary among patients and is dependent of a host of other factors, including the rheological properties of the red blood cells and relying solely on serum IgM for prediction of symptomatic hyperviscosity has its limitations. 13, 14 In fact, this variation in viscosity was also acknowledged by Waldenström in the first publication on this entity wherein a patient with serum globulin of 10.2 g/dL had serum viscosity of 3.7 cp and a patient with serum globulin value of 8.7 g/dL was associated with a serum viscosity of 6.2 cp. 7 Although the risk of hyperviscosity was higher in patients with a serum viscosity >1.8 cp at diagnosis, the absolute risk was still quite low, with only 6% patients developing symptomatic hyperviscosity in the following 12 months. Given such low rates of developing symptomatic hyperviscosity, even in the highrisk group, the strategy of pre-emptive therapy with its associated toxicities and costs does not appear to be ideal in managing these oth- Additionally, we found that approximately 50% of patients who exhibited symptomatic hyperviscosity had a serum viscosity that was less than 4 cp at the time of development of symptoms. Previous literature has suggested a very low probability of developing symptomatic hyperviscosity when serum viscosity is less than 4 cp, but those observations were primarily based on older studies with fewer patients. 5, 15, [26] [27] [28] With a large cohort of patients, our findings challenge the current dogma that symptomatic hyperviscosity is typically associated in patients with a serum viscosity of more than 4 cp, and the sole reliance on this threshold to attribute clinical manifestations to hyperviscosity could lead to misdiagnosis and delay in appropriate management.
The current study has the inherent limitations involved with any retrospective study, but in an indolent and rare disease such as WM, it is exceedingly difficult to conduct adequately powered prospective studies to address important questions pertaining to hyperviscosity.
There is also a concern of underlying subjectivity involved in selecting patients who require therapy at diagnosis. The reasons for the initiation of therapy in patients with WM who were diagnosed prior to 2002 may not have been completely in line with the Consensus criteria that were established in 2002. However, the practice patterns at our center over the past two decades have largely aligned to those envisaged in the Consensus criteria with therapy being indicated primarily for symptomatic patients or those with significant cytopenias. Also, this being a single-center study perhaps served to reduce the bias in treatment initiation, given the uniformity of management approach followed by our group. 1 Another potential limitation could be the difference in methodologies used for measurement of serum viscosity over time. However, these methods were internally validated and results have been presented in terms of the Sonoclot method, which is one of the most widely used methods for measurement of serum viscosity. Further, the occurrence of only a few events in the identification of predictors of time to development of symptomatic hyperviscosity could have limited the strength in our analysis, and it would be important for other groups to validate our findings.
| CONCLUSION
Our study demonstrates that the patients with IgM levels above 6000 mg/dL who are otherwise asymptomatic can be safely observed until development of the already established indication(s) for therapy. 11 Serum viscosity is an important part of the initial panel of investigations in patients with WM as it can vary widely among patients with similar IgM levels. Serum viscosity, and not serum IgM level at the time of diagnosis of WM appears to be an independent predictor of the time to development of subsequent symptomatic hyperviscosity in treatment-naïve patients. Lastly, the survival outcome of
patients with WM appears to be unaffected by the development of symptomatic hyperviscosity.
